PetCaseFinder

Peer-reviewed veterinary case report

New STAT3 inhibitor LLL12 slows growth of canine bone cancer cells

By Couto, Jason I et al.·Published in BMC veterinary research·2012·Department of Veterinary Biosciences, United States·View original on PubMed

PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →

Original publication title: Biologic activity of the novel small molecule STAT3 inhibitor LLL12 against canine osteosarcoma cell lines.

Species:
dog
OsteosarcomaMovement & jointsDogs

Plain-English summary

A study tested a new treatment called LLL12 on dog cancer cells from osteosarcoma, a type of bone cancer. The researchers found that LLL12 helped stop the cancer cells from growing and even caused some of them to die. When combined with the chemotherapy drug doxorubicin, LLL12 worked even better at fighting the cancer. This suggests that LLL12 could be a promising new option for treating osteosarcoma in dogs.

People also search for: dog osteosarcoma treatment · LLL12 for canine cancer · doxorubicin for dog cancer

Abstract

BACKGROUND: STAT3 [1] has been shown to be dysregulated in nearly every major cancer, including osteosarcoma (OS). Constitutive activation of STAT3, via aberrant phosphorylation, leads to proliferation, cell survival and resistance to apoptosis. The present study sought to characterize the biologic activity of a novel allosteric STAT3 inhibitor, LLL12, in canine OS cell lines. RESULTS: We evaluated the effects of LLL12 treatment on 4 canine OS cell lines and found that LLL12 inhibited proliferation, induced apoptosis, reduced STAT3 phosphorylation, and decreased the expression of several transcriptional targets of STAT3 in these cells. Lastly, LLL12 exhibited synergistic anti-proliferative activity with the chemotherapeutic doxorubicin in the OS lines. CONCLUSION: LLL12 exhibits biologic activity against canine OS cell lines through inhibition of STAT3 related cellular functions supporting its potential use as a novel therapy for OS.

Find similar cases for your pet

PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.

Search related cases →

Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/23244668/